Abstract
Rituximab is a chimeric monoclonal antibody targeting the pan-B-cell antigen CD20 and was the first monoclonal antibody approved for clinical use in the treatment of cancer. Since its first approval by the FDA in 1997, investigators have continued to explore a variety of clinical conditions in which rituximab has proven effective with minimal toxicity. Rituximab, as monotherapy or in combination with chemotherapy, has been studied extensively in untreated and relapsedrefractory settings as both induction and maintenance therapy for the treatment of CD20-positive lymphomas and chronic lymphocytic leukemia, in addition to non-malignant hematologic disorders including autoimmune hemolytic anemia and immune thrombocytopenic purpura. Here we discuss the clinical development of rituximab with a review of the efficacy data from clinical trials and its current status in the practice of hematology and oncology.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 71-82 |
| Number of pages | 12 |
| Journal | BioDrugs |
| Volume | 26 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2012 |
Fingerprint
Keywords
- Chronic-lymphocytic-leukaemia
- Diffuse-large-B-cell-lymphoma
- Follicular-lymphoma
- Haematological-disorders
- Lymphoma
- Rituximab
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
- Biotechnology
Cite this
Rituximab : Current status as therapy for malignant and Benign hematologic disorders. / Abdulla, Nihal E.; Ninan, Mary J.; Markowitz, Avi.
In: BioDrugs, Vol. 26, No. 2, 2012, p. 71-82.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Rituximab
T2 - Current status as therapy for malignant and Benign hematologic disorders
AU - Abdulla, Nihal E.
AU - Ninan, Mary J.
AU - Markowitz, Avi
PY - 2012
Y1 - 2012
N2 - Rituximab is a chimeric monoclonal antibody targeting the pan-B-cell antigen CD20 and was the first monoclonal antibody approved for clinical use in the treatment of cancer. Since its first approval by the FDA in 1997, investigators have continued to explore a variety of clinical conditions in which rituximab has proven effective with minimal toxicity. Rituximab, as monotherapy or in combination with chemotherapy, has been studied extensively in untreated and relapsedrefractory settings as both induction and maintenance therapy for the treatment of CD20-positive lymphomas and chronic lymphocytic leukemia, in addition to non-malignant hematologic disorders including autoimmune hemolytic anemia and immune thrombocytopenic purpura. Here we discuss the clinical development of rituximab with a review of the efficacy data from clinical trials and its current status in the practice of hematology and oncology.
AB - Rituximab is a chimeric monoclonal antibody targeting the pan-B-cell antigen CD20 and was the first monoclonal antibody approved for clinical use in the treatment of cancer. Since its first approval by the FDA in 1997, investigators have continued to explore a variety of clinical conditions in which rituximab has proven effective with minimal toxicity. Rituximab, as monotherapy or in combination with chemotherapy, has been studied extensively in untreated and relapsedrefractory settings as both induction and maintenance therapy for the treatment of CD20-positive lymphomas and chronic lymphocytic leukemia, in addition to non-malignant hematologic disorders including autoimmune hemolytic anemia and immune thrombocytopenic purpura. Here we discuss the clinical development of rituximab with a review of the efficacy data from clinical trials and its current status in the practice of hematology and oncology.
KW - Chronic-lymphocytic-leukaemia
KW - Diffuse-large-B-cell-lymphoma
KW - Follicular-lymphoma
KW - Haematological-disorders
KW - Lymphoma
KW - Rituximab
UR - http://www.scopus.com/inward/record.url?scp=84857836534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857836534&partnerID=8YFLogxK
U2 - 10.2165/11599500-000000000-00000
DO - 10.2165/11599500-000000000-00000
M3 - Article
VL - 26
SP - 71
EP - 82
JO - BioDrugs
JF - BioDrugs
SN - 1173-8804
IS - 2
ER -